Literature DB >> 16533265

Electrophysiology of pulmonary veins.

Yi-Jen Chen1, Shih-Ann Chen.   

Abstract

Pulmonary veins were found to be important foci for the genesis and maintenance of atrial fibrillation. Morphological studies have demonstrated the presence of complex anatomic structures and different types of cardiomyocytes in pulmonary veins. Numerous studies have suggested that the combination of reentrant and nonreentrant mechanisms (automaticity and triggered activity) are the underlying arrhythmogenic mechanisms of atrial fibrillation initiation from the pulmonary veins. Electropharmacological studies further indicated that pulmonary veins contained distinct arrhythmogenic activity. Several experimental models have been used to study the pulmonary vein electrical activity and demonstrate the precipitating factors for enhancing the pulmonary vein arrhythmogenic activity. The aim of this review article is to provide a critical overview of the current understanding of the basic and clinical electrophysiology of pulmonary veins and to underscore the importance of future research in this field.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533265     DOI: 10.1111/j.1540-8167.2005.00317.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  22 in total

1.  Three-dimensional speckle-tracking echocardiography for spatial evaluation of pulmonary vein (from the MAGYAR-Path Study).

Authors:  Attila Nemes; Péter Domsik; Anita Kalapos; Tamás Forster
Journal:  Quant Imaging Med Surg       Date:  2015-08

2.  Depolarization of the Rat Atria in Experimental Simulation of the Holiday Heart Syndrome.

Authors:  S L Smirnova; I M Roshchevskaya; V N Stolyaruk; M B Vititnova; I B Tsorin; S A Kryzhanovsky
Journal:  Dokl Biochem Biophys       Date:  2020-12-25       Impact factor: 0.788

3.  Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations.

Authors:  Serge Sicouri; Marc Pourrier; John K Gibson; Joseph J Lynch; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2011-10-20       Impact factor: 6.343

4.  Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves.

Authors:  Serge Sicouri; Leif Carlsson; Charles Antzelevitch
Journal:  J Pharmacol Exp Ther       Date:  2010-04-01       Impact factor: 4.030

5.  Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations.

Authors:  Serge Sicouri; Luiz Belardinelli; Leif Carlsson; Charles Antzelevitch
Journal:  J Cardiovasc Electrophysiol       Date:  2009-02-27

Review 6.  Nonpharmacologic management of atrial fibrillation: role of the pulmonary veins and posterior left atrium.

Authors:  Kalyanam Shivkumar; Eric Buch; Noel G Boyle
Journal:  Heart Rhythm       Date:  2009-12       Impact factor: 6.343

7.  Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria.

Authors:  Serge Sicouri; Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-12-01

8.  Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967.

Authors:  Serge Sicouri; Luiz Belardinelli; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2013-03-22       Impact factor: 6.343

9.  Sitagliptin Modulates the Electrical and Mechanical Characteristics of Pulmonary Vein and Atrium.

Authors:  Chien-Jung Chang; Ten-Fang Yang; Tin-I Lee; Yao-Chang Chen; Yu-Hsun Kao; Shih-Ann Chen; Yi-Jen Chen
Journal:  Acta Cardiol Sin       Date:  2014-01       Impact factor: 2.672

10.  The Electrical Characteristics and Clinical Significance of the Effect of Adenosine on Dissociated Activity after Circumferential Venous Isolation in Patients with Atrial Fibrillation.

Authors:  Ya-Lei Niu; Shih-Lin Chang; Yenn-Jiang Lin; Li-Wei Lo; Yu-Feng Hu; Ta-Chuan Tuan; Chin-Feng Tsai; Wei-Shiang Lin; Hsuan-Ming Tsao; Shih-Ann Chen
Journal:  Acta Cardiol Sin       Date:  2015-07       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.